Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019693 (HIV)
 170,526 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 34-year-old white man with the human immunodeficiency virus infection had a large Kaposi sarcoma lesion of his foot. This was treated with local radiation therapy consisting of 2700 rads administered in 15 fractions during a period of 28 days. Ten months later, the patient had painful disseminated Kaposi sarcoma and was treated with a 10 mg/m2 dose of intravenous vinblastine. Forty-eight hours after receiving the chemotherapy, the patient had an area of localized painful erythema develop, swelling, and vesicular eruption over the previous site of radiation therapy. This was healed by the fifth day after chemotherapy. No additional vinblastine was administered. Radiation recall occurring in a patient with significant immunosuppression (CD4 lymphocytes, 30 cells/microliters) possibly suggests that the tissue response is not a lymphocyte-mediated event.
Cancer 1992 Sep 15
PMID:Radiation recall associated with vinblastine in a patient treated for Kaposi sarcoma related to acquired immune deficiency syndrome. 151 13

Recent advances in clinical research on surface marker analysis of malignant lymphoma cells are reviewed. Malignant lymphoma can be classified into T-cell malignancy or B-cell malignancy, using flow cytometry or immunohistochemical analysis. Based on recent results of immunophenotypic analysis and clinical data, a new clinicopathologic classification of lymphoid malignancy is proposed. T-cell malignancy bearing T-cell receptor of gamma delta-type is discussed. Other recent topics on malignant lymphoma, such as B-cell lymphoma of the pleural cavity developing from long-standing pyothorax, mediastinal large-B-cell lymphoma with sclerosis, HIV-related B-cell lymphoma, and EB-virus genome carrying B-cell lymphoma in ATL are also discussed.
 ...
PMID:[Immunologic phenotype of malignant lymphoma]. 151 37

Elucidation of the mechanism by which viral infection induces the appearance of carbohydrate neoantigens is highly important. Results from such studies could be expected to be significant for a general understanding of the regulation of glycosylation, and perhaps especially important for the understanding of glycosylation in cancer. For anti-viral therapy in AIDS, inhibitors of glycosylation enzymes are very promising as their mode of action may preclude evolvement of resistent HIV substrains, which seems to be a common problem with the reverse transcriptase inhibitors presently used. Successful therapy with glycosylation enzyme inhibitors will, however, require the development of more specific and less toxic compounds. If carbohydrate antigens can elicit a neutralizing immune response in vivo, the possibility exists that carbohydrate neoantigens can be utilized in the construction of a vaccine against AIDS.
 ...
PMID:Carbohydrates of human immunodeficiency virus. 152 May 31

Involvement of the central nervous system (CNS) is common in patients with advanced disease due to human immunodeficiency virus (HIV). Symptoms range from lethargy and apathy to coma, incoordination and ataxia to hemiparesis, loss of memory to severe dementia, and focal to major motor seizures. Involvement may be closely associated with HIV infection per se, as in the AIDS dementia complex, but is frequently caused by opportunistic pathogens such as Toxoplasma gondii and Cryptococcus neoformans or malignancies such as primary lymphoma of the CNS. The clinical presentations of attendant and direct CNS involvement are remarkably non-specific and overlapping, yet a correct diagnosis is critical to successful intervention. Toxoplasmic encephalitis is one of the most common and most treatable causes of AIDS-associated pathology of the CNS. A great deal has been learned in the last 10 years about its unique presentation in the HIV-infected patient with advanced disease. Drs. Benjamin J. Luft of the State University of New York at Stony Brook and Jack S. Remington of the Stanford University School of Medicine and Palo Alto Medical Foundation's Research Institute have studied T. gondii for many years and are two of the leading experts in the field. This commentary comprises an update of their initial review (J Infect Dis 1988;157:1-6) and a presentation of the current approaches to diagnosing and managing toxoplasmic encephalitis in HIV-infected patients.
 ...
PMID:Toxoplasmic encephalitis in AIDS. 152 Jul 57

Infections and malignancies account for most deaths in patients with AIDS and will continue to do so as long as HIV-induced immunosuppression is progressive and irreversible. Co-trimoxazole has emerged as the preferred agent for prevention of Pneumocystis carinii pneumonia. As appropriate broad-spectrum agents are developed, multiple opportunistic pathogen prophylaxis could become effective.
 ...
PMID:Current status of HIV therapy: II. Opportunistic diseases. 152 56

The recombinant plasmid pBHIV1 carrying the long terminal repeat (LTR) of the human immunodeficiency virus 1 (HIV-1), linked to the chloramphenicol acetyl transferase (CAT) gene, was introduced into human and rat fibroblasts. Stable transfectants resistant to geneticin expressed CAT activity from the HIV-1 LTR. It was found that the cytotoxic drug cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) (carboplatin) at concentrations from 1 x 10(-6) to 1 x 10(-4) M does not stimulate the expression of CAT from the HIV-1 LTR. These results differ from previous studies with the related drug cis-diamminedichloroplatinum(II) which showed stimulation of gene expression from the HIV-1 LTR and suggest that carboplatin could be used in the treatment of cancer patients with Acquired Immune Deficiency Syndrome.
 ...
PMID:Carboplatin as opposed to cisplatin does not stimulate the expression of the human immunodeficiency virus long terminal repeat sequences. 154 Feb 20

Polyadenylic-polyuridylic acid referred to as poly(A).poly(U) is a synthetic double-stranded RNA which has been shown to manifest both antitumoral and immunomodulatory activities. Here we used this agent to demonstrate its antiviral activity against the human immunodeficiency virus (HIV-1 and HIV-2). Treatment of cells with poly(A).poly(U) resulted in a significant delay in the development of the HIV-specific cytopathic effect characterized by the formation of syncytia and cell lysis. Furthermore, the production of virus measured by the concentration of the HIV major core protein was reduced by 90-95%. Under these experimental conditions, the synthesis of HIV proteins was reduced at least tenfold whereas the metabolism and proliferation of cells apparently were not affected. The inhibitory action of poly(A).poly(U) seems to be at the level of viral entry into cells. Combined treatment of infected cells with poly(A).poly(U) and azidothymidine (AZT) resulted in a 4-5-fold synergistic inhibitory effect. Previously, no toxicity has been observed in cancer patients with long-term treatment with poly(A).poly(U). In view of this and the significant anti-HIV effect, poly(A).poly(U) provides a potential candidate as a therapeutic drug in AIDS disease.
 ...
PMID:Antiviral action of polyadenylic-polyuridylic acid against HIV in cell cultures. 154 Apr 14

The replication cycle of human immunodeficiency virus type 1 (HIV-1) consists of four distinct stages, each of which can be targeted for specific antiviral chemotherapy. The stages are (1) the attachment of virus to the CD4 receptor at the cell surface; (2) the uncoating of viral nucleic acid and its conversion via viral reverse transcriptase activity to DNA; (3) cellular multiplication, accompanied by the replication of integrated proviral DNA and production of viral RNA and proteins; and (4) the assembly and liberation of progeny virus from the cell and the potential reinitiation of the replication cycle in previously uninfected cells. Since each of these steps represents a potential target for anti-HIV chemotherapy, it is apparent that the rationale for the use of antiviral drugs is not dissimilar from the manner in which antineoplastic agents are targeted to specific stages in the replication cycle of tumor cells. As in the case of anticancer chemotherapy, it is hoped that combinations of drugs, which act against different steps in the viral replication cycle, might have synergistic potential. AZT or zidovudine is the most widely used drug to date to impede the replication of HIV-1; it is significant that this compound was designed initially with anticancer chemotherapy in mind. Although AZT therapy has been reasonably successful, this drug has had important toxic side effects. As in the case of many cancer chemotherapeutic agents, drug resistance to AZT is likely to be an important problem, and there have been several reports of the isolation of drug-resistant variants of HIV-1.
Cancer Invest 1992
PMID:Strategies in the treatment of AIDS and related diseases: the lessons of cancer chemotherapy. 155 Oct 24

Potential availability of transplantable organs from different types of injury fatalities was studied. Factors examined included target organ damage or disease, age of potential donor, duration of survival before circulatory arrest, and universal rejection factors such as sepsis, HIV infection, or systemic malignancy. Motor vehicle fatalities yielded the greatest proportion of potentially viable organs. Delay in discovery and universal rejection factors were important exclusionary issues for fatalities from suicide, homicide, and non-motor vehicle unintentional injury. There was no difference in organ damage or in duration of survival with higher speeds in fatal crashes, suggesting that states with 65 mph speed limits--and consequently higher death rates--may have greater potential availability of donatable organs than do those with 55 mph maximum. The increase in deaths at higher speeds, however, vastly outweighs the benefits of any possible increase in the potential for donor organs.
 ...
PMID:Potential availability of transplantable organs according to factors associated with type of injury event. 155 28

In a review of the literature it is shown that most HIV-infected patients experience psychoreactive disorders early in the course of the disease and psycho-organic disorders at its more advanced stages. The latter are due either to the HIV itself or to opportunistic infections and malignancies. Differential diagnoses comprise adverse-effects of chemotherapeutics or illicit drugs and, in addition, independent psychiatric disorders certains of which may be over-represented in high-risk groups. Diagnostic and therapeutic strategies are reviewed.
 ...
PMID:[Psychiatric diseases in patients with HIV infection]. 157 Mar 67


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>